Teprotumumab for the treatment of thyroid eye disease

References

• Smith TJ, Hegedüs L, Longo DL. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Kahaly GJ. Graves’ orbitopathy: a multidisciplinary approach - questions and answers. Basel: Karger; 2017. p. 1–25.
   Google Scholar
• Cockerham KP, Padnick-Silver L, Stuertz N, et al. Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther. 2021;10(4):975–987.
   PubMed Web of Science ®Google Scholar
• Wang Y, Padnick-Silver L, Francis-Sedlak M, et al. Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States. Endocr Pract. 2022;28(9):842–846.
   PubMed Web of Science ®Google Scholar
• Perricone C, Versini M, Ben-Ami D, et al. Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev. 2016;15(4):354–374.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Ragusa F, et al. Graves’ disease: epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101387.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al. European Group on Graves’ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9–26.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–352.
   PubMed Web of Science ®Google Scholar
• Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94–105.
   PubMedGoogle Scholar
• Antonelli A, Fallahi P, Elia G, et al. Graves’ disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101388.
   PubMed Web of Science ®Google Scholar
• Kotwal A, Stan M. Thyrotropin receptor antibodies-an overview. Ophthalmic Plast Reconstr Surg. 2018;34(4SSuppl 1):S20–S27.
   PubMedGoogle Scholar
• Kahaly GJ, Diana T, Kanitz M, et al. Prospective trial of functional thyrotropin receptor antibodies in graves disease. J Clin Endocrinol Metab. 2020;105(4):e1006–14.
   PubMed Web of Science ®Google Scholar
• Wall JR, Lahooti H. Pathogenesis of thyroid eye disease—does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol. 2011;62(Suppl 1):1–7.
   PubMedGoogle Scholar
• Diana T, Brown RS, Bossowski A, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves’ disease-a multicenter study. J Clin Endocrinol Metab. 2014;99(5):1648–1655.
   PubMed Web of Science ®Google Scholar
• Place RF, Krieger CC, Neumann S, et al. Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves’ ophthalmopathy: studies in orbital fibroblasts in vitro. Br J Pharmacol. 2017;174(4):328–340.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Tsai CC, Shih MJ, et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18(9):983–988.
   PubMed Web of Science ®Google Scholar
• Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological aspects of graves’ ophthalmopathy. Biomed Res Int. 2019;2019:7453260.
   PubMed Web of Science ®Google Scholar
• Elia G, Fallahi P, Ragusa F, et al. Precision medicine in graves’ disease and ophthalmopathy. Front Pharmacol. 2021;12:754386.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Elia G, et al. Cytokines as targets of novel therapies for graves’ ophthalmopathy. Front Endocrinol (Lausanne). 2021;12:654473.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid- associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95(1):430–438.
   PubMed Web of Science ®Google Scholar
• Dolman PJ. Evaluating Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229–248.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010;62(2):199–236.
   PubMed Web of Science ®Google Scholar
• Tramontano D, Cushing GW, Moses AC, et al. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology. 1986;119(2):940–942.
   PubMed Web of Science ®Google Scholar
• Krieger CC, Perry JD, Morgan SJ, et al. TSH/IGF-1 receptor cross-talk rapidly activates extracellular signal-regulated kinases in multiple cell types. Endocrinology. 2017;158(10):3676–3683.
   PubMed Web of Science ®Google Scholar
• Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348–6354.
   PubMed Web of Science ®Google Scholar
• Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397–4405.
   PubMed Web of Science ®Google Scholar
• Strianese D, Rossi F. Interruption of autoimmunity for thyroid eye disease: b-cell and T-cell strategy. Eye (Lond). 2019;33(2):191–199.
   PubMed Web of Science ®Google Scholar
• Wakelkamp IM, Bakker O, Baldeschi L, et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf). 2003;58(3):280–287.
   PubMed Web of Science ®Google Scholar
• Mikoś H, Mikoś M, Obara-Moszyńska M, et al. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65(2):150–155.
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–738.
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Lösch C, Glowacka D, et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93(8):1052–1056.
   PubMed Web of Science ®Google Scholar
• Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.
   PubMedGoogle Scholar
• Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–290.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18(3):333–346.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101383.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454–4463.
   PubMed Web of Science ®Google Scholar
• Ponto KA, Pitz S, Pfeiffer N, et al. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int. 2009;106(17):283–289.
   PubMed Web of Science ®Google Scholar
• Ponto KA, Hommel G, Pitz S, et al. Quality of life in a German graves orbitopathy population. Am J Ophthalmol. 2011;152(3):483–90.e1.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves’ ophthalmopathy. Acta Endocrinol (Copenh). 1992;126(1):13–23.
   PubMedGoogle Scholar
• Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol. 2021;13:25158414211027760.
   Web of Science ®Google Scholar
• Markham A. Teprotumumab: first approval. Drugs. 2020;80(5):509–512.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761.
   PubMed Web of Science ®Google Scholar
• Xin Y, Xu F, Gao Y, et al. Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease. Clin Pharmacokinet. 2021;60(8):1029–1040.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360–372.
   PubMed Web of Science ®Google Scholar
• Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–185.
   PubMed Web of Science ®Google Scholar
• Chen J, von Bartheld CS. Role of exogenous and endogenous trophic factors in the regulation of extraocular muscle strength during development. Invest Ophthalmol Vis Sci. 2004;45(10):3538–3545.
   PubMed Web of Science ®Google Scholar
• Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001;54(3):391–398.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Dermatologic and ophthalmic Drugs Advisory Committee meeting sponsor briefing document: teprotumumab for injection. Available from: https://www.fda.gov/media/133429/download
   Google Scholar
• Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438–449.
   PubMed Web of Science ®Google Scholar
• van Geest RJ, Sasim IV, Koppeschaar HP, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158(2):229–237.
   PubMed Web of Science ®Google Scholar
• Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–332.
   PubMed Web of Science ®Google Scholar
• Gao G, Dai J, Qian Y, et al. Meta-analysis of methylprednisolone pulse therapy for Graves’ ophthalmopathy. Clin Exp Ophthalmol. 2014;42(8):769–777.
   PubMed Web of Science ®Google Scholar
• Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94(8):2708–2716.
   PubMed Web of Science ®Google Scholar
• Mourits MP, van Kempen-Harteveld ML, García MB, et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355(9214):1505–1509.
   PubMed Web of Science ®Google Scholar
• Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432–441.
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422–431.
   PubMed Web of Science ®Google Scholar
• Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–190.
   PubMed Web of Science ®Google Scholar
• Silkiss RZ, Paap MK, Roelofs KA, et al. Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can J Ophthalmol. 2021;56(1):66–70.
   PubMed Web of Science ®Google Scholar
• Sy A, Eliasieh K, Silkiss RZ. Clinical response to tocilizumab in severe thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2017;33(3):e55–e57.
   PubMed Web of Science ®Google Scholar
• Silkiss RZ, Reier A, Coleman M, et al. Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2010;26(5):310–314.
   PubMed Web of Science ®Google Scholar
• Douglas RS, Dailey R, Subramanian PS, et al. Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol. 2022;140(4):328–335.
   PubMed Web of Science ®Google Scholar
• Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1 R expression. Eye (Lond). 2021;35(9):2607–2612.
   PubMed Web of Science ®Google Scholar
• Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020 May 15;19:100744.
   PubMedGoogle Scholar
• Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2022;36(8):1553–1559.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: https://clinicaltrials.gov
   Google Scholar
• Sears CM, Wang Y, Bailey LA, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep. 2021;23:101111.
   PubMedGoogle Scholar
• Chow A, Silkiss RZ. Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Rep. 2022;15(4):e248335.
   PubMedGoogle Scholar
• Safo MB, Silkiss RZ. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Am J Ophthalmol Case Rep. 2021;22:101069.
   PubMedGoogle Scholar
• Shah SA, Lu T, Yu M, et al. Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapies. Invest Ophthalmol Vis Sci. 2022;63(7):4002–A0344 .
   Web of Science ®Google Scholar
• Dosiou C, Kossler AL. Thyroid eye disease: navigating the new treatment landscape. J Endocr Soc. 2021;5(5):bvab034.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Understanding unapproved use of approved drugs “off label.” Available from: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
   Google Scholar
• Neumann S, Nir EA, Eliseeva E, et al. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinology. 2014;155(1):310–314.
   PubMed Web of Science ®Google Scholar
• Neumann S. Small molecule agonists and antagonists as potential new therapeutics targeting the TSH receptor. Endocrine Abstracts. 2017;49(NSA5.2).
   Google Scholar
• Marcinkowski P, Hoyer I, Specker E, et al. A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of graves’ orbitopathy. Thyroid. 2019;29(1):111–123.
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Spirig R, Baz Morelli A, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tian Z, Thirumalai D, et al. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. J Drug Target. 2014;22(4):269–278.
   PubMed Web of Science ®Google Scholar
• Immunovant.com. New York (NY): immunovant, 2020. Available from: https://www.immunovant.com/investors/news-events/press-releases/detail/16/immunovant-announces-positive-clinical-results-from-ongoing
   Google Scholar
• Kahaly GJ, Stan MN, Frommer L, et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-a proof-of-concept trial. J Clin Endocrinol Metab. 2020;105(3):dgz013.
   PubMed Web of Science ®Google Scholar
• Plöhn S, Hose M, Schlüter A, et al. Fingolimod improves the outcome of experimental Graves’ disease and associ- ated orbitopathy by modulating the autoimmune response to the thyroid-stimulating hormone receptor. Thyroid. 2019;29(9):1286–1301.
   PubMed Web of Science ®Google Scholar